Oxidized proteins and oxidized protein inhibitor...

Details Oxidized proteins and oxidized protein inhibitor... Oxidized proteins and oxidized protein inhibitor...

2001-10-19

2011-10-11

Russel, Jeffrey E (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S013300, C514S013700, C514S014900

Reexamination Certificate

active

08034769

ABSTRACT:
The invention relates to substances which inhibit the binding of oxidized proteins to CD36 or inhibit the functions of CD36 that are induced by the interaction of CD36 with oxidized proteins. The invention also relates to the use of these substances as medicaments for humans and animals. In one embodiment, a medicament includes an oxidized protein, an oxidized peptide, or structural analog or mimetic thereof. Methods for prophylaxis or therapy of acute infections, inhibition of angiogenesis, and improvement of hemostasis include administering to an animal or human in need thereof an effective amount of a medicament including an oxidized protein, an oxidized peptide, or structural analog or mimetic thereof. An example of an acute infection is Human Immunodeficiency Virus (HIV).

REFERENCES:
patent: 4035483 (1977-07-01), Bunyan
patent: 5045531 (1991-09-01), Berkowitz et al.
patent: 5366440 (1994-11-01), Fossel
patent: 5552307 (1996-09-01), Kessler et al.
patent: 5776912 (1998-07-01), Patel et al.
patent: 6193953 (2001-02-01), Lohrmann et al.
patent: 6251868 (2001-06-01), Kubota et al.
patent: 6265377 (2001-07-01), Dasseux et al.
patent: 6270791 (2001-08-01), Van Dyke et al.
patent: 6312713 (2001-11-01), Korol et al.
patent: 6953666 (2005-10-01), Kinkade et al.
patent: 7388075 (2008-06-01), Kehrel et al.
patent: 91/10684 (1991-07-01), None
patent: WO 96/16663 (1996-06-01), None
patent: WO 97/21443 (1997-06-01), None
patent: 00/28072 (2000-05-01), None
CD36 Mediates the In Vitro Inhibitory Effects of Thrombospondin-1 on Endothelial Cells, The Journal of Cell Biology, David W. Dawson, Aug. 11, 1997, vol. 138, No. 2, pp. 707-717.
Lovaststin Reduces Expression of the Combined Adhesion and Scavenger Receptor CD36 in Human Monocytic Cells, Biochemical Pharmacology, Angelika Pietsch, vol. 52, pp. 433-439, 1996.
Oxidized Low-Density Lipoprotein Induces Macrophage Respiratory Burst via its Protein Moiety: A Novel Pathway in Atheregenesis, Biochemical and Biophysical Research Communications , Thao Nguyen-Khoa et al., pp. 804-809, vol. 263, No. 3. Oct. 5, 1999.
Activation of Primary Human Monocytes by the Oxidized Form of a1-Antitrypsin, The Journal of Biological Chemistry, Fabian Moraga et al., vol. 275, No. 11, 2000, pp. 7693-7700.
Identification of a CD36-Related Thrombospondin 1-Binding Domain in HIV-1 Envelope Glycoprotein GP120: Relationship to HIV-1-Specific Inhibitory Factors in Human Saliva, J. Exp. Med., Rene Crombie et al., vol. 187, No. 1, Jan. 5, 1998, pp. 25-35.
Peroxynitrite-Mediated Oxidation of Fibrinogen Inhibits Clot Formation, Federation of European Biochemical Societies, G. Lupidi et al., pp. 236-240, vol. 462, No. 3. Dec. 3, 1999.
Hazell, et al., “Oxidation of Low-Density Lipoprotein with Hypochlorite Causes Transformation of the Lipoprotein”, Biochem. J., vol. 290, No. 1, 1993, pp. 165-172.
Nozaki, et al., “Reduced Uptake of Oxidized Low Density Lipoproteins in Monocyte-Derived Macrophages,” J. Clin. Invest., vol. 96, No. 4, Oct. 1995, pp. 1859-1865.
Yamaguchi, et al., “PS-Liposome and Ox-LDL Bind to Different Sites of the Immunodominant Domain (#155-183) of CD36,” Thrombosis Research, vol. 97, No. 5, 2000. pp. 317-326.
Nakata, et al., “CD36, A Novel Receptor for Oxidized Low-Density Lipoproteins is Highly Expressed,” Arterioscler. Thromb. Vasc. Biol., vol. 19, No. 5, 1999, pp. 1333-1339.
Endemann, et al., “CD36 is a Receptor for Oxidized Low Density Lipoprotein,” J. Biol. Chem., vol. 268, No. 16, 1999, pp. 11811-11816.
Luc, et al., “Oxidation of Lipoproteins and Atherosclerosis,” Am. J. Clin. Nutr., vol. 53, No. 1, pp. 206S-209S, (1991).
Schacter, et al., “Oxidative Modification of Fibrinogen Inhibits Thrombin-Catalyzed Clot Formation,” Free Radical Biol. Med., vol. 18, No. 4, 1995, pp. 815-821.
Bergt, et al., “Hypochlorite Modification of High Density Lipoprotein: Effects on Cholesterol Efflux From J774 Macrophages,” FEBS LEtt., vol. 452, No. 3, 1999, pp. 295-300.
Carr, et al., “Oxidation of Neutrophil Glutathione and Protein Thiols by Myeloperoxidase-derived Hypochlorous Acid”, Biochem. J., vol. 327, 1997, pp. 275-281.
Glutathione, http://en.wikipedia.org/wiki/Glutathione., downloaded 2010.

Affiliated with

Also associated with

Rating

Oxidized proteins and oxidized protein inhibitor... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Oxidized proteins and oxidized protein inhibitor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oxidized proteins and oxidized protein inhibitor... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4280094